Big-Pharma Partner Harbour BioMed Boosts Stake In Spruce Biosciences

Group 1: Harbour BioMed's Acquisition and Stake in Spruce Biosciences - Harbour BioMed exercised its warrant to acquire common stock in Spruce Biosciences, holding approximately 3.8% of total outstanding shares and 3.1% of fully diluted shares [1] - The warrant was issued to Harbour BioMed's subsidiary and minority shareholders of HBM Alpha Therapeutics in connection with a license and collaboration agreement with Spruce [2] Group 2: Collaboration and Development Efforts - The collaboration aims to advance the development of SPR202, a selective anti-corticotropin-releasing hormone monoclonal antibody for various disorders, including congenital adrenal hyperplasia [3] - Spruce Biosciences secured loan funding of up to $50 million from Avenue Capital Group for growth capital [3] Group 3: Strategic Collaborations and Financial Opportunities - Harbour BioMed announced a global strategic collaboration with AstraZeneca, established in March 2025, and a multi-year collaboration with Bristol Myers Squibb in December 2025 [4] - Potential payments to Harbour BioMed from Bristol Myers Squibb could total $90 million, with development and commercial milestones up to $1.035 billion, along with tiered royalties [5] Group 4: Market Performance of Spruce Biosciences - Benzinga Edge ranks Spruce Biosciences' momentum as weak, with a score of 21 out of 100, indicating underperformance relative to the broader market [6] - Spruce Biosciences shares were unchanged at $71.45 during premarket trading, near its 52-week low of $7.26 [7]